Zenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Zenas BioPharma is set to announce its Q2 2025 earnings on August 21st, with analysts predicting a loss of ($1.02) per share and revenue of $1.25 million.
• The company's shares rose by 5.1% and have a market capitalization of approximately $698.98 million, with recent price movements reflecting a 1-year low of $5.83 and a high of $26.25.
• Research analysts have reaffirmed strong ratings for Zenas BioPharma, with price objectives of $30.00 and $35.00 from HC Wainwright and Wedbush, respectively.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 21st. Analysts expect the company to announce earnings of ($1.02) per share and revenue of $1.25 million for the quarter.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.23).

Zenas BioPharma Trading Up 5.1%

Shares of NASDAQ ZBIO opened at $16.71 on Thursday. The business's fifty day moving average is $12.48. Zenas BioPharma has a 1-year low of $5.83 and a 1-year high of $26.25. The firm has a market capitalization of $698.98 million and a P/E ratio of -4.71.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ZBIO shares. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Zenas BioPharma in a report on Friday, May 16th. Wedbush reaffirmed an "outperform" rating and set a $35.00 price objective on shares of Zenas BioPharma in a report on Thursday, May 15th.

Hedge Funds Weigh In On Zenas BioPharma

An institutional investor recently raised its position in Zenas BioPharma stock. Rhumbline Advisers increased its position in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) by 71.3% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 19,721 shares of the company's stock after purchasing an additional 8,207 shares during the quarter. Rhumbline Advisers' holdings in Zenas BioPharma were worth $191,000 as of its most recent filing with the SEC.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.